Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity.

Wan N, Rahman A, Hitomi H, Nishiyama A.

Front Endocrinol (Lausanne). 2018 Jul 26;9:421. doi: 10.3389/fendo.2018.00421. eCollection 2018.

2.

Low Body Mass Index is a Poor Prognosis Factor in Cardioembolic Stroke Patients with NonValvular Atrial Fibrillation.

Hagii J, Metoki N, Saito S, Fujita A, Shiroto H, Sasaki S, Takahashi K, Hitomi H, Baba Y, Seino S, Kamada T, Uchizawa T, Iwata M, Matsumoto S, Yasujima M, Tomita H.

J Stroke Cerebrovasc Dis. 2018 Nov;27(11):3155-3162. doi: 10.1016/j.jstrokecerebrovasdis.2018.07.002. Epub 2018 Aug 6.

PMID:
30093200
3.

A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice.

Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, Kobara H, Sugaya T, Nishiyama A.

Kidney Int. 2018 Sep;94(3):524-535. doi: 10.1016/j.kint.2018.05.002. Epub 2018 Jul 23.

PMID:
30045814
4.

Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats.

Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, Masaki T, Nakano D, Hitomi H, Kobori H, Nishiyama A.

J Pharmacol Sci. 2018 Jun;137(2):220-223. doi: 10.1016/j.jphs.2017.10.006. Epub 2017 Oct 28.

5.

A novel approach to adenine-induced chronic kidney disease associated anemia in rodents.

Rahman A, Yamazaki D, Sufiun A, Kitada K, Hitomi H, Nakano D, Nishiyama A.

PLoS One. 2018 Feb 7;13(2):e0192531. doi: 10.1371/journal.pone.0192531. eCollection 2018.

6.

Hypertension with diabetes mellitus complications.

Yamazaki D, Hitomi H, Nishiyama A.

Hypertens Res. 2018 Mar;41(3):147-156. doi: 10.1038/s41440-017-0008-y. Epub 2018 Jan 22. Review.

PMID:
29353881
7.

A protease-activated receptor-1 antagonist protects against podocyte injury in a mouse model of nephropathy.

Guan Y, Nakano D, Zhang Y, Li L, Liu W, Nishida M, Kuwabara T, Morishita A, Hitomi H, Mori K, Mukoyama M, Masaki T, Hirano K, Nishiyama A.

J Pharmacol Sci. 2017 Sep 14. pii: S1347-8613(17)30128-7. doi: 10.1016/j.jphs.2017.09.002. [Epub ahead of print]

8.

Corrigendum for "Impact of Atrial Natriuretic Peptide Value for Predicting Paroxysmal Atrial Fibrillation in Ischemic Stroke Patients" [J Stroke Cerebrovasc Dis. 2017;26:772-778].

Shiroto H, Tomita H, Hagii J, Metoki N, Fujita A, Kamada T, Takahashi K, Saito S, Sasaki S, Hitomi H, Seino S, Baba Y, Uchizawa T, Iwata M, Matsumoto S, Yasujima M, Okumura K.

J Stroke Cerebrovasc Dis. 2018 Jan;27(1):276. doi: 10.1016/j.jstrokecerebrovasdis.2017.10.004. Epub 2017 Nov 3. No abstract available.

PMID:
29103859
9.

Human pluripotent stem cell-derived erythropoietin-producing cells ameliorate renal anemia in mice.

Hitomi H, Kasahara T, Katagiri N, Hoshina A, Mae SI, Kotaka M, Toyohara T, Rahman A, Nakano D, Niwa A, Saito MK, Nakahata T, Nishiyama A, Osafune K.

Sci Transl Med. 2017 Sep 27;9(409). pii: eaaj2300. doi: 10.1126/scitranslmed.aaj2300.

PMID:
28954928
10.

Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats.

Ansary TM, Fujisawa Y, Rahman A, Nakano D, Hitomi H, Kobara H, Masaki T, Titze JM, Kitada K, Nishiyama A.

Sci Rep. 2017 Aug 25;7(1):9555. doi: 10.1038/s41598-017-09352-5.

11.

IBMX protects human proximal tubular epithelial cells from hypoxic stress through suppressing hypoxia-inducible factor-1α expression.

Hasan AU, Kittikulsuth W, Yamaguchi F, Musarrat Ansary T, Rahman A, Shibayama Y, Nakano D, Hitomi H, Tokuda M, Nishiyama A.

Exp Cell Res. 2017 Sep 15;358(2):343-351. doi: 10.1016/j.yexcr.2017.07.007. Epub 2017 Jul 6.

PMID:
28689812
12.

How should we treat patients with primary aldosteronism to prevent new-onset diabetes mellitus?

Hitomi H, Nishiyama A.

J Hypertens. 2017 Aug;35(8):1575-1576. doi: 10.1097/HJH.0000000000001440. No abstract available.

PMID:
28657976
13.

Establishment of a new medical school in the Tohoku region after the Great East Japan Earthquake.

Furukawa K, Ohara T, Miyazawa I, Sumitomo K, Hitomi H.

Geriatr Gerontol Int. 2017 Apr;17(4):663-664. doi: 10.1111/ggi.12905. No abstract available.

PMID:
28405969
14.

Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.

Rahman A, Hitomi H, Nishiyama A.

Hypertens Res. 2017 Jun;40(6):535-540. doi: 10.1038/hr.2016.193. Epub 2017 Jan 19. Review.

PMID:
28100918
15.

Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats.

Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A.

Clin Exp Pharmacol Physiol. 2017 Apr;44(4):522-525. doi: 10.1111/1440-1681.12725.

PMID:
28063156
16.

Impact of Atrial Natriuretic Peptide Value for Predicting Paroxysmal Atrial Fibrillation in Ischemic Stroke Patients.

Shiroto H, Tomita H, Hagii J, Metoki N, Fujita A, Kamada T, Takahashi K, Saito S, Sasaki S, Hitomi H, Seino S, Baba Y, Uchizawa T, Iwata M, Matsumoto S, Yasujima M, Okumura K.

J Stroke Cerebrovasc Dis. 2017 Apr;26(4):772-778. doi: 10.1016/j.jstrokecerebrovasdis.2016.10.016. Epub 2016 Nov 18. Erratum in: J Stroke Cerebrovasc Dis. 2018 Jan;27(1):276.

PMID:
27876310
17.

Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.

Mizushige T, Kobori H, Hitomi H, Nishijima Y, Tomoda F, Morimoto S, Kohno M, Nishiyama A.

Int J Mol Sci. 2016 Oct 27;17(11). pii: E1800.

18.

Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement.

Hagii J, Tomita H, Metoki N, Tamai Y, Saito S, Shiroto H, Hitomi H, Kamada T, Seino S, Takahashi K, Sasaki S, Yasujima M, Okumura K.

Thromb Res. 2016 Dec;148:9-14. doi: 10.1016/j.thromres.2016.10.011. Epub 2016 Oct 13.

PMID:
27764730
19.

Hormonal changes following a low-salt diet in patients with Ménière's disease.

Miyashita T, Inamoto R, Fukuda S, Hoshikawa H, Hitomi H, Kiyomoto H, Nishiyama A, Mori N.

Auris Nasus Larynx. 2017 Feb;44(1):52-57. doi: 10.1016/j.anl.2016.03.001. Epub 2016 Mar 28.

PMID:
27033030
20.

Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.

Rahman A, Kittikulsuth W, Fujisawa Y, Sufiun A, Rafiq K, Hitomi H, Nakano D, Sohara E, Uchida S, Nishiyama A.

J Hypertens. 2016 May;34(5):893-906. doi: 10.1097/HJH.0000000000000871.

PMID:
26982381
21.

[BASELINE SCREENING USING INTERFERON-GAMMA RELEASE ASSAY SUGGESTS AN INCREASED RISK OF MYCOBACTERIUM TUBERCULOSIS INFECTION AMONG EMPLOYEES IN A JAPANESE GENERAL HOSPITAL].

Abe T, Hashimoto T, Kobayashi T, Hitomi H, Ebina M, Fujimori J, Ami Y, Hayakawa S, Fujimura S.

Kekkaku. 2015 Sep;90(9):625-30. Japanese.

PMID:
26761994
22.

Impact of Sex Difference on Severity and Functional Outcome in Patients with Cardioembolic Stroke.

Tomita H, Hagii J, Metoki N, Saito S, Shiroto H, Hitomi H, Kamada T, Seino S, Takahashi K, Baba Y, Sasaki S, Uchizawa T, Iwata M, Matsumoto S, Shoji Y, Tanno T, Osanai T, Yasujima M, Okumura K.

J Stroke Cerebrovasc Dis. 2015 Nov;24(11):2613-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.07.016. Epub 2015 Sep 2.

PMID:
26341732
23.

Severity and Functional Outcome of Patients with Cardioembolic Stroke Occurring during Non-vitamin K Antagonist Oral Anticoagulant Treatment.

Tomita H, Hagii J, Metoki N, Saito S, Shiroto H, Hitomi H, Kamada T, Seino S, Takahashi K, Sasaki S, Yasujima M, Okumura K.

J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1430-7. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.004. Epub 2015 Apr 2.

PMID:
25843224
24.

Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type I diabetic kidney.

Morita T, Nakano D, Kitada K, Morimoto S, Ichihara A, Hitomi H, Kobori H, Shiojima I, Nishiyama A.

Eur J Pharmacol. 2015 Jun 5;756:85-91. doi: 10.1016/j.ejphar.2015.03.053. Epub 2015 Mar 26.

25.

Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin.

Hagii J, Tomita H, Metoki N, Saito S, Shiroto H, Hitomi H, Kamada T, Seino S, Takahashi K, Baba Y, Sasaki S, Uchizawa T, Iwata M, Matsumoto S, Osanai T, Yasujima M, Okumura K.

Stroke. 2014 Sep;45(9):2805-7. doi: 10.1161/STROKEAHA.114.006661. Epub 2014 Jul 31.

PMID:
25082810
26.

Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy.

Kitada K, Nakano D, Ohsaki H, Hitomi H, Minamino T, Yatabe J, Felder RA, Mori H, Masaki T, Kobori H, Nishiyama A.

J Diabetes Complications. 2014 Sep-Oct;28(5):604-11. doi: 10.1016/j.jdiacomp.2014.05.010. Epub 2014 Jun 4.

27.

Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency.

Yasuno T, Osafune K, Sakurai H, Asaka I, Tanaka A, Yamaguchi S, Yamada K, Hitomi H, Arai S, Kurose Y, Higaki Y, Sudo M, Ando S, Nakashima H, Saito T, Kaneoka H.

Biochem Biophys Res Commun. 2014 May 30;448(2):175-81. doi: 10.1016/j.bbrc.2014.04.084. Epub 2014 Apr 26.

PMID:
24780397
28.

Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardioembolic stroke patient.

Saito S, Tomita H, Kimura Y, Shiroto H, Hagii J, Metoki N, Hitomi H, Kamada T, Osanai T, Okumura K, Yasujima M.

J Stroke Cerebrovasc Dis. 2014 Jul;23(6):1747-9. doi: 10.1016/j.jstrokecerebrovasdis.2014.01.014. Epub 2014 Apr 13.

PMID:
24725815
29.

Chymase activities and survival in endotoxin-induced human chymase transgenic mice.

Rafiq K, Fan YY, Sherajee SJ, Takahashi Y, Matsuura J, Hase N, Mori H, Nakano D, Kobara H, Hitomi H, Masaki T, Urata H, Nishiyama A.

Int J Med Sci. 2014 Jan 11;11(3):222-5. doi: 10.7150/ijms.7382. eCollection 2014.

30.

Calcium channel blocker enhances beneficial effects of an angiotensin II AT1 receptor blocker against cerebrovascular-renal injury in type 2 diabetic mice.

Rafiq K, Sherajee SJ, Hitomi H, Nakano D, Kobori H, Ohmori K, Mori H, Kobara H, Masaki T, Kohno M, Nishiyama A.

PLoS One. 2013 Dec 10;8(12):e82082. doi: 10.1371/journal.pone.0082082. eCollection 2013.

31.

Aldosterone aggravates glucose intolerance induced by high fructose.

Sherajee SJ, Rafiq K, Nakano D, Mori H, Kobara H, Hitomi H, Fujisawa Y, Kobori H, Masaki T, Nishiyama A.

Eur J Pharmacol. 2013 Nov 15;720(1-3):63-8. doi: 10.1016/j.ejphar.2013.10.051. Epub 2013 Nov 4.

32.

High sodium augments angiotensin II-induced vascular smooth muscle cell proliferation through the ERK 1/2-dependent pathway.

Liu G, Hitomi H, Rahman A, Nakano D, Mori H, Masaki T, Ma H, Iwamoto T, Kobori H, Nishiyama A.

Hypertens Res. 2014 Jan;37(1):13-8. doi: 10.1038/hr.2013.108. Epub 2013 Sep 12.

33.

Roles of Na⁺/H⁺ exchanger type 1 and intracellular pH in angiotensin II-induced reactive oxygen species generation and podocyte apoptosis.

Liu Y, Hitomi H, Diah S, Deguchi K, Mori H, Masaki T, Nakano D, Kobori H, Nishiyama A.

J Pharmacol Sci. 2013;122(3):176-83. Epub 2013 Jun 22.

34.

Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.

Ohnishi K, Murase M, Nakano D, Pelisch N, Hitomi H, Kobori H, Morimoto S, Mori H, Masaki T, Ohmori K, Kohno M, Ichihara A, Nishiyama A.

J Pharmacol Sci. 2013;122(2):103-8. Epub 2013 May 22.

35.

Risk of sweet 'ethylene glycol' consumption.

Fujita T, Nakamura N, Hitomi H, Okumura K.

Intern Med. 2013;52(3):409. Epub 2013 Feb 1. No abstract available.

36.

Effects of angiotensin II AT₁-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats.

Kosaka S, Pelisch N, Rahman M, Nakano D, Hitomi H, Kobori H, Fukuoka N, Kobara H, Mori H, Masaki T, Cervenka L, Matsumura Y, Houchi H, Nishiyama A.

J Pharmacol Sci. 2013;121(2):95-102. Epub 2013 Jan 22.

37.

Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats.

Fan YY, Kobori H, Nakano D, Hitomi H, Mori H, Masaki T, Sun YX, Zhi N, Zhang L, Huang W, Zhu B, Li P, Nishiyama A.

Horm Metab Res. 2013 May;45(5):338-43. doi: 10.1055/s-0032-1331256. Epub 2013 Jan 15.

38.

Role of (pro)renin receptor in Ang II-mediated EGF receptor transactivation.

Shibayama Y, Hitomi H, Nakano D, Kobori H, Mori H, Deguchi K, Masaki T, Ichihara A, Nishiyama A.

Front Biosci (Elite Ed). 2013 Jan 1;5:697-705.

39.

Important aspects of urine sampling for angiotensinogen measurement: time and preservation conditions in healthy individuals.

Nishijima Y, Kobori H, Sofue T, Kaifu K, Moriwaki K, Hara T, Hitomi H, Kohno M, Nishiyama A.

Tohoku J Exp Med. 2012 Dec;228(4):333-9.

40.

Aldosterone induces p21-regulated apoptosis via increased synthesis and secretion of tumour necrosis factor-α in human proximal tubular cells.

Kitada K, Nakano D, Hitomi H, Kobori H, Deguchi K, Mori H, Masaki T, Nishiyama A.

Clin Exp Pharmacol Physiol. 2012 Oct;39(10):858-63. doi: 10.1111/j.1440-1681.2012.12001.x.

41.

Case reports of primary pulmonary adenocarcinoma with pleural spread: so-called pseudomesotheliomatous adenocarcinoma.

Saito R, Kasajima A, Taniuchi S, Fujishima F, Ishida K, Nakamura Y, Yamanda S, Takahashi T, Hitomi H, Murakami K, Watanabe M, Sasano H.

Pathol Int. 2012 Oct;62(10):709-15. doi: 10.1111/j.1440-1827.2012.02860.x.

PMID:
23005599
42.

Multiphoton imaging of the glomerular permeability of angiotensinogen.

Nakano D, Kobori H, Burford JL, Gevorgyan H, Seidel S, Hitomi H, Nishiyama A, Peti-Peterdi J.

J Am Soc Nephrol. 2012 Nov;23(11):1847-56. doi: 10.1681/ASN.2012010078. Epub 2012 Sep 20.

43.

Oxidative stress-induced glomerular mineralocorticoid receptor activation limits the benefit of salt reduction in Dahl salt-sensitive rats.

Kitada K, Nakano D, Liu Y, Fujisawa Y, Hitomi H, Shibayama Y, Shibata H, Nagai Y, Mori H, Masaki T, Kobori H, Nishiyama A.

PLoS One. 2012;7(7):e41896. doi: 10.1371/journal.pone.0041896. Epub 2012 Jul 24.

44.

N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition.

Lei B, Nakano D, Fujisawa Y, Liu Y, Hitomi H, Kobori H, Mori H, Masaki T, Asanuma K, Tomino Y, Nishiyama A.

J Pharmacol Sci. 2012;119(4):359-67. Epub 2012 Jul 21.

45.

Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan.

Lei B, Nakano D, Fan YY, Kitada K, Hitomi H, Kobori H, Mori H, Masaki T, Nishiyama A.

J Pharmacol Sci. 2012;119(2):131-8. Epub 2012 May 22.

46.

Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation.

Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, Suzuki F, Nagai Y, Nakano D, Hitomi H, Kitada K, Urushihara M, Kobori H, Kohno M, Nishiyama A.

Circulation. 2012 Mar 20;125(11):1402-13. doi: 10.1161/CIRCULATIONAHA.111.064097. Epub 2012 Feb 10.

47.

Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.

Sofue T, Kiyomoto H, Kobori H, Urushihara M, Nishijima Y, Kaifu K, Hara T, Matsumoto S, Ichimura A, Ohsaki H, Hitomi H, Kawachi H, Hayden MR, Whaley-Connell A, Sowers JR, Ito S, Kohno M, Nishiyama A.

Am J Hypertens. 2012 May;25(5):604-11. doi: 10.1038/ajh.2012.1. Epub 2012 Feb 9.

48.

Short-Term Calorie Restriction in Early Life Attenuates the Development of Proteinuria but Not Glucose Intolerance in Type 2 Diabetic OLETF Rats.

Nakano D, Diah S, Kitada K, Hitomi H, Mori H, Masaki T, Kobori H, Nishiyama A.

ISRN Endocrinol. 2011;2011:768637. doi: 10.5402/2011/768637. Epub 2011 Nov 16.

49.

Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor.

Sherajee SJ, Fujita Y, Rafiq K, Nakano D, Mori H, Masaki T, Hara T, Kohno M, Nishiyama A, Hitomi H.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):257-63. doi: 10.1161/ATVBAHA.111.240697. Epub 2011 Dec 15.

PMID:
22173225
50.

Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.

Nakano D, Lei B, Kitada K, Hitomi H, Kobori H, Mori H, Deguchi K, Masaki T, Minamino T, Nishiyama A.

Am J Hypertens. 2012 Mar;25(3):354-8. doi: 10.1038/ajh.2011.224. Epub 2011 Nov 24.

Supplemental Content

Loading ...
Support Center